

Neurological Disorder Drugs Market Expected to Reach US\$ 112 Billion with CAGR 5% by 2027 | Transparency Market Research

Neurological disorder drugs market is driven by rise in prevalence of neurology disorders among geriatric population and increase in therapeutic treatments

increasing R&D spending across the world.

TRANSPARENCY

MARKET RESEARCH
In depth analysis, accurate results

Neurological Disorder Drugs Market

Neurological Disorder Drugs market in terms of revenue is poised to reach US\$ 112 Billion by 2027, growing at a CAGR of 5.0% from 2019 to 2027 according to a latest report published by Transparency Market Research.

000000 00000000:-

A neurological disease occurs when any portion of the brain or nervous system malfunctions,

causing physical and/or psychological symptoms. Neurological disorders are treated with a variety of medications, including antipsychotics, antiepileptics, anticholinergics, and analgesics. Furthermore, the drug that is prescribed is primarily determined by the patient's neurological condition. These medications aid in the management of neurological conditions, symptom reduction, and improved quality of life. Corticosteroids, which are widely used to treat multiple sclerosis and help reduce inflammation, are among the most commonly used neurological medications.

Globally, neurological disorders are the main cause of death. It is defined as both central and peripheral nervous system disorders. The diseases primarily affect the elderly population. It may progress and necessitate long-term treatment. Congenital neurological abnormalities appear during the early stages of embryo development and can be detected at birth. A variety of factors, such as traumatic brain injuries, immunological problems, postnatal injections, spinal cord injuries, neoplasia, and exposure to ambient chemicals or poisons, can cause acquired neurological disorders after birth. Many bacterial, viral, fungal, and parasite diseases can damage the nervous system, resulting in neurological illnesses.

- In terms of region, the global neurological disorder drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
- The current and future market sizes in terms of revenue (US\$ Mn) of these regional markets and their major countries have been provided in the report by 2027, along with their CAGRs for the period from 2019 to 2027
- The study also offers a list of recommendations, highlights, and useful insights of the market, which will help new companies willing to enter the market and existing companies to increase market shares, and help in the decision-making process

000000 000000:

The rise in usage of Artificial intelligence and Machine Learning in the current care of neurological disorders

Growing neurological disorders worldwide can provide emerging prospects for drug retailers Breakthrough research in neurological disorders can provide pharmaceuticals companies with increased opportunities for their market growth

000000 0000000:

Increased awareness about available preventive drugs for diseases like dementia, epilepsy, multiple sclerosis and migraine, owing to advancements in drug technology

Presence of large geriatric population suffering from neurological problems like Alzheimer's disease and Parkinson's disease

Provision of affordable drugs inconsideration with developing and underdeveloped countries Research and development initiatives for drug formulations are expensive

- Novartis AG
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd.
- Pfizer
- · Bayer AG
- · Boehringer Ingelheim GmbH
- AstraZeneca
- Teva Pharmaceutical Industries
- Merck & Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.
- · Amgen, Inc.
- UCB S.A.
- Eli Lilly and Company
- Biogen

https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=76505

000000 00000 000 000000 0000:-

Disorder

- Epilepsy
- · Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Cerebrovascular Diseases
- Others

Drug Class

- Anticholinergic
- Antiepileptic
- Antipsychotic
- Hypnotic & Sedatives
- Analgesics
- Antihypertensive
- Anticoagulants
- Others

Distribution Channel

- Retail Pharmacies
- · Hospital Pharmacies
- Online Pharmacies

NAN ANNA NANA MANANA MANANANANANA MANANA MANANA MANA

- The report offers statistical data in terms of value (US\$) as well as Volume (units)
- Exclusive insight into the key trends affecting this industry, although key threats, opportunities and disruptive technologies that could shape the Global Market supply and demand
- The report tracks the leading market players that will shape and impact this Market most
- The data analysis present in this report is based on the combination of both primary and secondary resources
- The report helps you to understand the real effects of key market drivers or retainers on this business

Advancements and Breakthroughs in the **Disinfectants Market**

Sales Developments in Clinical Trials Market 2021-2031

Nikhil Sawlani

Transparency Market Research Inc.

+ +1 518-618-1030

sales@transparencymarketresearch.com

Visit us on social media:

Twitter

LinkedIn

YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/655249461

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.